|
Video: What is a Stock Split?
|
|
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. Co. is focused on the development of novel therapeutics for a range of cancer indications. Co.'s product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. According to our SLS split history records, SELLAS Life Sciences Group has had 2 splits. | |
|
SELLAS Life Sciences Group (SLS) has 2 splits in our SLS split history database. The first split for SLS took place on January 02, 2018. This was a 1 for 30 reverse split, meaning for each 30 shares of SLS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split. SLS's second split took place on November 08, 2019. This was a 1 for 50 reverse split, meaning for each 50 shares of SLS owned pre-split, the shareholder now owned 1 share. For example, a 33.3333333333333 share position pre-split, became a 0.666666666666667 share position following the split.
When a company such as SELLAS Life Sciences Group conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SLS split history from start to finish, an original position size of 1000 shares would have turned into 0.666666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SELLAS Life Sciences Group shares, starting with a $10,000 purchase of SLS, presented on a split-history-adjusted basis factoring in the complete SLS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/21/2015 |
|
End date: |
01/16/2025 |
|
Start price/share: |
$2,400.00 |
|
End price/share: |
$0.98 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.96% |
|
Average Annual Total Return: |
-54.19% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4.09 |
|
Years: |
9.99 |
|
|
|
Date |
Ratio |
01/02/2018 | 1 for 30 | 11/08/2019 | 1 for 50 |
|
|